Sumitomo Pharma provides innovative pharmaceuticals and healthcare solutions. It concentrates on the pharmaceutical business as its core activity and carries out other operations covering food ingredients, chemical product materials, and animal health products. The company’s focus areas for the pharmaceutical business are Psychiatry and Neurology, Diabetes, and Rare diseases. In the Psychiatry and Neurology area, the company provides therapeutic drugs for Parkinson’s disease and schizophrenia. In the Diabetes area, Sumitomo offers drugs with different mechanisms of action and responds to a range of medical needs.

Through its food ingredients and food additives business, the company develops and sells food ingredients and additives for the manufacture of safe and high-quality foods. Products include polysaccharides, primarily GLYLOID (tamarind seed gum), and seasonings such as soup or bouillon. The chemical product materials business covers pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. The animal health products business offers veterinary medicines and other products for companion animals, primarily dogs and cats, and for livestock such as cattle, swine, poultry, horses, and aqua-cultured fish.

Sumitomo Pharma’s focus areas of research are psychiatry and neurology, oncology, and regenerative medicine and cell therapy. It is working on a malaria vaccine with Ehime University and a universal influenza vaccination with the National Institute of Infectious Diseases. The company’s newly approved drugs include KYNMOBI (apomorphine HCl), TWYMEEG (imeglimin), ORGOVYX (relugolix), RETHYMIC (allogeneic processed thymus tissue-agdc), and MYFEMBREE (relugolix combination tablet).